Science & Medicine
Genta filed for permission Tuesday to begin testing the first therapeutic drug that incorporates molecules that some scientists say could hold the key to treating diseases now considered incurable.
Aug. 28, 1991
World & Nation
Isis Pharmaceuticals, a 2-year-old biotechnology company that is trying to develop products to treat cancer and certain viral diseases, announced a multimillion-dollar cooperative agreement with a major Japanese drug company, its third major deal with an outside drug concern in two months.
Dec. 19, 1990
Business
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research.
Sept. 17, 2002
Swiss pharmaceuticals giant Ciba-Geigy said Tuesday that it will invest more than $30 million over the next five years in ISIS Pharmaceuticals, a young biotechnology company based in Carlsbad that is developing a series of therapeutic drugs to combat cancer and other diseases.
Oct. 31, 1990
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment.
Jan. 11, 2005
Pharmaceuticals: The biotech firm will be paid $200 million over four years. Its shares rise 48% on the news.
Aug. 23, 2001
In a stunning setback, Isis Pharmaceuticals Inc. of Carlsbad, Calif., said its leading drug candidate -- a novel therapy for lung cancer -- failed in a closely watched test of 616 patients.
March 18, 2003
Swiss pharmaceuticals giant Ciba-Geigy said Tuesday that it will invest more than $30 million over the next five years in Isis Pharmaceuticals, a young biotechnology company based in Carlsbad that is developing a series of therapeutic drugs to combat cancer and other diseases.
As ISIS Pharmaceuticals President Stanley Crooke walked through his company’s newly leased Carlsbad facility, he took pains to point out that, despite the mostly vacant office and laboratory space, his new biotechnology firm is hard at work developing products at a temporary lab in Sorrento Valley.
May 30, 1989
Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. have formed a venture uniting Nobel Prize winners David Baltimore and Phillip Sharp to create drugs from a newly discovered class of genetic material.
Sept. 8, 2007